

Synaffix enables ADCs for oncology that are both safer and more effective as well as easier to manufacture




About Synaffix

Formed in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on continued advancement of our best-in-class antibody-drug conjugate (ADC) technology platform. As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, our vision is to become the preferred partner in the development of these complex biological therapeutics and realize our ambition – **connect to cure™**.

We are backed by a top tier, life science-focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and Merck Ventures the strategic corporate venture capital fund of Merck.

Our antibody conjugation technology, GlycoConnect™, enables the design of complex biological drugs without the need for prior antibody engineering yet comes with specificity and precision similar to what is used to design modern small molecule drugs. Combined with our payload-enhancing linker technology, HydraSpace™, and the superior stability and efficacy offered by our proprietary BCN-based metal-free click chemistry, the resulting ADCs come with an expanded therapeutic index (TI) and improved manufacturability.

Our technology allows initiation of clinical trials within a year from preclinical proof-of-concept. We anticipate the first-in-human studies with glycan conjugated ADCs to be initiated by our partners in 2017.



Technology Snapshot

We are critically focused on enabling our partners with the most advanced suite of tools available for the design and development of ADCs that can be targeted against a wide variety of cancer types and can generate proof-of-concept ADCs in just a matter of weeks.

Key features of Synaffix ADC technology:

- No need for mAb or cell line engineering
- Homogenous and highly stable ADC products
- Compatible with any IgG isotype and all key payload classes
- Efficient conjugation of highly hydrophobic payloads
- Low propensity to aggregate
- Site-Specific
- DAR2, DAR4 and Dual-Warhead (DAR2+2) ADC formats
- Rapid and predictable scalability to multi-gram scale
- COGs comparable to ThioMAB ADCs

Management Team

Peter van de Sande
MSc, MBA, MBL
Chief Executive Officer

Floris van Delft
PhD
Founder & Chief Scientific Officer

Sander van Berkel
PhD
Founder & Director, R&D Operations

Anthony DeBoer
Director, Business Development

Board of Directors

Konstantinos Efthymiopoulos
PhD, MBA
Independent Chairman

Simon Nebel
PhD, MBA
Managing Partner
Aravis

Edward van Wezel
MSc
Managing Partner
BioGeneration Ventures

Hakan Goker
PhD
Investment Director
Merck Ventures

Peter van de Sande
Chief Executive Officer - (see above)

Investors

Aravis
Switzerland

BioGeneration Ventures
Netherlands

Merck Ventures
Germany / Netherlands

BOM Capital
Netherlands


Series A financing completed Feb 2014.

GlycoConnect™ and HydraSpace™

GlycoConnect™ underpins the Synaffix ADC technology platform, utilizing enzymatic modification of the 2 naturally-occurring glycan anchor points that exist on all antibodies to facilitate efficient, site-specific and stable conjugation of potent anti-cancer molecules using extensively optimized metal-free click chemistry.

The aromatic linker stability that is afforded by the use of click chemistry ensures that more of the toxic payload reaches the targeted cancer cell, increasing efficacy, while minimizing the potential for the payload to detach prematurely in circulation, improving the safety profile. These two features, combined with the high homogeneity afforded by our approach, enhance the therapeutic index of the resulting ADC product.


The overall GlycoConnect™ process yield from the antibody starting material is typically >75% and results in a homogenous ADC drug product.



Schematic overview of the GlycoConnect™ process

Dual-Warhead ADCs

Enabled by HydraSpace™



HydraSpace™ is a payload-enhancing linker technology that is compatible with our site-specific antibody conjugation technology and offers the following additional advantages:

- Reduces ADC aggregation potential
- Increases payload solubility
- Improves conjugation efficiency and speed
- Branching capability enables higher drug loading
- Enables "Dual-Warhead" ADC format with two mechanisms of action

IP Portfolio

The Synaffix IP portfolio is comprised of 18 patent applications and granted patents that are necessary and useful to generate and sell Synaffix ADCs. Filed and granted claims cover key aspects of Synaffix ADC technology including:

- GlycoConnect™ site-specific antibody conjugation technology
- HydraSpace™ payload-enhancing linker technology
- BCN metal-free click chemistry

Technology Partnerships

Our vision is to be the preferred technology partner, driving continued innovation in the field of ADCs for oncology that are both safer and more effective as well as easier to manufacture.

We can generate nonclinical proof-of-concept (POC) material in just a few weeks. Further, we enable rapid development of ADC product candidates by our partners with a timeline to IND filing as short as 12 months from preclinical POC.

As a first step, we welcome the opportunity to showcase the advantages of our approach under a joint POC study.

In October 2016, Synaffix entered into a license agreement with ADC Therapeutics, the first announced of several undisclosed collaborations.

Scientific Advisory Board

Hans-Joachim Boehm, PhD

Former Global Head of
Small Molecule Research, Roche

Stan van Boeckel, PhD

Professor of Industrial Medicinal
Chemistry, Leiden Institute of Chemistry

Jason Chin, PhD

Professor of Chemistry & Chemical
Biology, University of Cambridge

Luca Gianni, MD

Director of Medical Oncology,
San Raffaele Hospital

George Sledge, MD

Professor and Chief of Medical Oncology,
Stanford University Medical Center

Contact

Pivot Park, RE Building
Industrielaan 63
5349 AE Oss, Netherlands

(tel) +31 88 022 4505

(fax) +31 88 022 4555

bd@synaffix.com